In South Korea, lazertinib monotherapy was approved in 2021 for the treatment of patients with the EGFR T790M mutation in tumor tissues or plasma after unsuccessful treatment with either first‐ or second‐generation TKI agents [9]. Here, EGFR is linked to neoplasm.